Pulmonary Hypertension Associated with Left-Sided Heart Disease

Heart Failure Clinics

Volumn 8, Issue 3, 2012, Pages 447-459

  Barnett, Christopher F ^a   De Marco, Teresa ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Heart failure; Heart transplant; Pulmonary hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; NESIRITIDE; PROSTACYCLIN; SILDENAFIL; TADALAFIL; TEZOSENTAN;

ACUTE HEART FAILURE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; EXERCISE TOLERANCE; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART TRANSPLANTATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MEAN ARTERIAL PRESSURE; MITRAL VALVE REGURGITATION; OXYGEN SATURATION; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHEAR STRESS; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE;

CALCIUM CHANNEL BLOCKERS; ENDOTHELINS; HEART DISEASES; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PHOSPHODIESTERASE 5 INHIBITORS; PROGNOSIS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84863101704     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.04.009     Document Type: Review

References (69)

1. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S43-S54.
2. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 350(9):886-895.
3. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):e391-e479.
4. Khush K.K., Tasissa G., Butler J., et al. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. Am Heart J 2009, 157(6):1026-1034.
5. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009, 53(13):1119-1126.
6. Costard-Jackle A., Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992, 19(1):48-54.
7. Bonow R.O., Carabello B.A., Chatterjee K., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006, 48(3):e1-e148.
8. Braunwald E., Braunwald N.S., Ross J., et al. Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med 1965, 273:509-514.
9. Kuznetsova T., Herbots L., Lopez B., et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009, 2(2):105-112.
10. Pieske B. Heart failure with preserved ejection fraction-a growing epidemic or 'The Emperor's New Clothes?'. Eur J Heart Fail 2011, 13(1):11-13.
11. Abramson S.V., Burke J.F., Kelly J.J., et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992, 116(11):888-895.
12. Chatterjee N.A., Lewis G.D. What is the prognostic significance of pulmonary hypertension in heart failure?. Circ Heart Fail 2011, 4(5):541-545.
13. Aronson D., Eitan A., Dragu R., et al. The relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail 2011, 4(5):644-650.
14. Cappola T.P., Felker G.M., Kao W.H., et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002, 105(14):1663-1668.
15. Bursi F., McNallan S.M., Redfield M.M., et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 2012, 59(3):222-231.
16. Lewis G.D., Murphy R.M., Shah R.V., et al. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes/clinical perspective. Circ Heart Fail 2011, 4(3):276-285.
17. Kang D.H., Kim J.H., Rim J.H., et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 2009, 119(6):797-804.
18. Chen J.M., Levin H.R., Michler R.E., et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 1997, 114(4):627-634.
19. Erickson K.W., Costanzo-Nordin M.R., O'Sullivan E.J., et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Lung Transplant 1990, 9(5):526-537.
20. Mandeep R.M., Jon K., Randall S., et al. Listing criteria for heart transplantation: international society for heart and lung transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant 2006, 25(9):1024-1042.
21. Butler J., Stankewicz M.A., Wu J., et al. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. J Heart Lung Transplant 2005, 24(2):170-177.
22. Drazner M.H., Hamilton M.A., Fonarow G., et al. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999, 18(11):1126-1132.
23. Delgado J.F., Conde E., Sánchez V., et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005, 7(6):1011-1016.
24. Moraes D.L., Colucci W.S., Givertz M.M. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102(14):1718-1723.
25. Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109(2):159-165.
26. Cargill R.I., Lipworth B.J. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chest 1996, 109(2):424-429.
27. Bristow M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101(5):558-569.
28. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group. J Am Coll Cardiol 1983, 2(4):755-763.
29. Ferreira A.J., Shenoy V., Yamazato Y., et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179(11):1048-1054.
30. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346(12):896-903.
31. Hiroe M., Hirata Y., Fujita N., et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991, 68(10):1114-1115.
32. Cody R.J., Haas G.J., Binkley P.F., et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992, 85(2):504-509.
33. Pacher R., Stanek B., Hulsmann M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27(3):633-641.
34. Nagueh S.F., Appleton C.P., Gillebert T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22(2):107-133.
35. Hoeper M.M., Lee S.H., Voswinckel R., et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006, 48(12):2546-2552.
36. Shah S.J., Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 2008, 300(4):431-433.
37. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997, 134(1):44-54.
38. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. JAMA 2002, 287(12):1531-1540.
39. Michaels A.D., Chatterjee K., De Marco T. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail 2005, 11(6):425-431.
40. 2010 clinical trial/clinical science abstracts. Circulation 2010, 122(21):2215-2226.
41. Sitbon O., Humbert M., Jaïs X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111(23):3105-3111.
42. Cowburn P.J., Cleland J.G. Endothelin antagonists for chronic heart failure: do they have a role?. Eur Heart J 2001, 22(19):1772-1784.
43. Kelland N.F., Webb D.J. Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart 2007, 93(1):2-4.
44. Sutsch G., Kiowski W., Yan X.W., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998, 98(21):2262-2268.
45. Packer M., McMurray J., Massie B.M., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005, 11(1):12-20.
46. Teerlink J.R. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?. J Card Fail 2002, 8(3):124-127.
47. Kalra P.R., Moon J.C., Coats A.J. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?. Int J Cardiol 2002, 85(2-3):195-197.
48. Luscher T.F., Enseleit F., Pacher R., et al. Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure: the heart failure ETA receptor blockade trial (HEAT). Circulation 2002, 106(21):2666-2672.
49. Anand P.I., McMurray P.J., Cohn J.N., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364(9431):347-354.
50. Kaluski E., Kobrin I., Zimlichman R., et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003, 41(2):204-210.
51. Barnett C.F., Machado R.F. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006, 2(4):411-422.
52. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353(20):2148-2157.
53. Galiè N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119(22):2894-2903.
54. Kumar P., Francis G.S., Tang W.H. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nat Rev Cardiol 2009, 6(5):349-355.
55. Goldsmith S.R. Type 5 phosphodiesterase inhibition in heart failure: the next step. J Am Coll Cardiol 2007, 50(22):2145-2147.
56. Alaeddini J., Uber P.A., Park M.H., et al. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004, 94(11):1475-1477.
57. Lepore J.J., Maroo A., Bigatello L.M., et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005, 127(5):1647-1653.
58. Lewis G.D., Lachmann J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115(1):59-66.
59. Guazzi M., Samaja M., Arena R., et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007, 50(22):2136-2144.
60. Guazzi M., Vicenzi M., Arena R., et al. PDE5-inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry and clinical status in patients with stable systolic heart failure: results of a 1-year prospective, randomized, placebo-controlled study. Circ Heart Fail 2011, 4(1):8-17.
61. Guazzi M., Vicenzi M., Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail 2012, 14(1):82-90.
62. Guazzi M., Vicenzi M., Arena R., et al. Pulmonary hypertension in heart failure with preserved ejection fraction/clinical perspective. Circulation 2011, 124(2):164-174.
63. Klotz S., Wenzelburger F., Stypmann J., et al. Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant. Ann Thorac Surg 2006, 82(5):1770-1773.
64. Beyersdorf F., Schlensak C., Berchtold-Herz M., et al. Regression of " fixed" pulmonary vascular resistance in heart transplant candidates after unloading with ventricular assist devices. J Thorac Cardiovasc Surg 2010, 140(4):747-749.
65. Sansone F., Rinaldi M. Oral sildenafil: potential role in heart transplantation. Review of the literature and personal experience. J Cardiol 2010, 55(3):291-295.
66. Garrity E.R., Moore J., Mulligan M.S., et al. Heart and lung transplantation in the United States, 1996-2005. Am J Transplant 2007, 7:1390-1403.
67. Deuse T., Sista R., Weill D., et al. Review of heart-lung transplantation at Stanford. Ann Thorac Surg 2010, 90(1):329-337.
68. Nair P.K., Kormos R.L., Teuteberg J.J., et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. J Heart Lung Transplant 2010, 29(2):201-208.
69. Zimpfer D., Zrunek P., Sandner S., et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 2007, 31(4):698-702.